Skip To The Main Content

Browse these ideas available for licensing that have the potential to improve lives while creating jobs to support and grow the region.

All technologies
 are listed as non-confidential technical summaries.

Technologies were generated by academic institutions, entrepreneurs, and corporations.

Click the Tech Search button below to have Whiteboard 2 Boardroom® staff complete a personalized search for innovations to license from our research institution partners.

The most recent innovations from our partners are featured separately and organized by category. All listings are updated as new technology opportunities become available. 

For assistance in connecting with, or attaining further information on any of these technologies, please contact us.

Antiviral Therapy Against Mosquito-Borne Rift Valley Fever Virus

Researchers have developed a potential antiviral therapy against Rift Valley Fever Virus (RVFV) infection using sequence-selective siRNA inhibition. RVFV causes mosquito-borne illness and is recognized as a “Category A” Priority Pathogen, which affects human and animal populations in Africa and the Middle East. Although not endemic in North America and Europe, it has the potential to expand its range to these regions and is also a potential tool for bioterrorism. Currently, no effective therapy exists against RVFV. Existing antiviral drugs have been used to treat human infections, albeit with serious side effects.

Researchers have developed therapeutic siRNA duplexes as a potential therapy against RVFV. This siRNA-mediated therapy is expected to cause minimal or no side effects, by working to directly silence the nucleoprotein gene of the RVFV and suppress its replication. The nucleoprotein gene was specifically targeted as it is a highly conserved viral gene and less prone to mutations. Additionally, if any mutations were to occur in the viral genome, then a simple change in the nucleotide sequence of the siRNA would address the problem and provide an effective cure. Alternatively, the therapy can involve the simultaneous use of several siRNA duplexes that target different areas of the viral nucleoprotein, to further overcome any possible resistance due to mutations.

  • Significantly inhibits viral protein expression and viral replication
  • Expected to cause minimal to no side effects
  • Development of resistance due to viral mutations can be easily addressed by redesigning the siRNA construct
  • siRNAs specifically target the viral nucleoprotein gene, which is a highly conserved gene and less prone to mutations
  • Possible mutations at the specific nucleoprotein gene locus can be overcome by the use of several siRNA duplexes that target different areas of the nucleoprotein gene

The RVFV-specific siRNA duplexes may be used to treat humans and animals infected with Rift Valley Fever Virus.

Additional Details


Kansas State University

Intellectual Property Protection

Pending Patent

Interested? Request More Information